Pure Autonomic Failure
26
6
6
15
Key Insights
Highlights
Success Rate
79% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
15.4%
4 terminated out of 26 trials
78.9%
-7.6% vs benchmark
4%
1 trials in Phase 3/4
33%
5 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (26)
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
Automated Abdominal Binder for Orthostatic Hypotension
[18F]F-DOPA Imaging in Patients With Autonomic Failure
Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension
CPAP for the Treatment of Supine Hypertension
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
Biomarkers of Risk of Parkinson Disease
Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms
Natural History Study of Synucleinopathies
Synuclein-One Study
Concentration and Attentional Deficits in POTS and Other Autonomic Neuropathies
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
Local Heat Stress in Autonomic Failure Patients With Supine Hypertension
The Role of Endothelin in the Supine Hypertension of Autonomic Failure
Anti-Cholinergic Receptors Antibodies, Autonomic Profile and Dysautonomia Symptoms in PAF, ALS and POTS (DISAUT-AB)
Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure
Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease
Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure
The Autonomic Nervous System and Obesity